Dynavax Technologies Corporation (NASDAQ: DVAX) is 10.56% higher on its value in year-to-date trading and has touched a low of $1.80 and a high of $12.44 in the current 52-week trading range. The DVAX stock was last observed hovering at around $4.92 in the last trading session, with the day’s gains setting it 0.13% off its average median price target of $14.00 for the next 12 months. It is also 74.75% off the consensus price target high of $20.00 offered by 4 analysts, but current levels are 63.93% higher than the price target low of $14.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $5.05, the stock is 2.52% and 9.06% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.26 million and changing 2.54% at the moment leaves the stock -8.60% off its SMA200. DVAX registered -12.61% loss for a year compared to 6-month loss of -42.19%. The firm has a 50-day simple moving average (SMA 50) of $4.87 and a 200-day simple moving average (SMA200) of $5.85.
The stock witnessed a 6.03% gain in the last 1 month and extending the period to 3 months gives it a 10.81%, and is 6.49% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.62% over the week and 7.19% over the month.
Dynavax Technologies Corporation (DVAX) has around 231 employees, a market worth around $529.10M and $37.60M in sales. Distance from 52-week low is 180.29% and -59.44% from its 52-week high. The company has generated returns on investments over the last 12 months (-72.10%).
Dynavax Technologies Corporation (DVAX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Dynavax Technologies Corporation (DVAX) is a “Buy”. 4 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Dynavax Technologies Corporation is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.23 with sales reaching $13.06M over the same period.The EPS is expected to grow by 15.10% this year, but quarterly earnings will post 13.70% year-over-year. Quarterly sales are estimated to grow 23.60% in year-over-year returns.
Dynavax Technologies Corporation (DVAX) Top Institutional Holders
213 institutions hold shares in Dynavax Technologies Corporation (DVAX), with 832.91k shares held by insiders accounting for 0.76% while institutional investors hold 81.48% of the company’s shares. The shares outstanding are 109.82M, and float is at 108.02M with Short Float at 22.59%. Institutions hold 80.86% of the Float.
The top institutional shareholder in the company is State Street Corporation with over 11.6 million shares valued at $50.13 million. The investor’s holdings represent 10.53% of the DVAX Shares outstanding. As of Sep 29, 2020, the second largest holder is Federated Hermes, Inc. with 10.95 million shares valued at $47.29 million to account for 9.94% of the shares outstanding. The other top investors are Bain Capital Life Sciences Investors, LLC which holds 10.9 million shares representing 9.89% and valued at over $47.07 million, while Blackrock Inc. holds 7.41% of the shares totaling 8.16 million with a market value of $35.27 million.
Dynavax Technologies Corporation (DVAX) Insider Activity
A total of 1 insider transactions have happened at Dynavax Technologies Corporation (DVAX) in the last six months, with sales accounting for 1 and purchases happening 0 times. The most recent transaction is an insider sale by Janssen Robert, the company’s Senior Vice President. SEC filings show that Janssen Robert sold 50,000 shares of the company’s common stock on Jul 17 at a price of $11.09 per share for a total of $0.55 million. Following the sale, the insider now owns 0.13 million shares.
Dynavax Technologies Corporation disclosed in a document filed with the SEC on May 27 that Hack Andrew A. F. (Director) bought a total of 1,000,000 shares of the company’s common stock. The trade occurred on May 27 and was made at $5.00 per share for $5.0 million. Following the transaction, the insider now directly holds 8.53 million shares of the DVAX stock.
Still, SEC filings show that on May 19, Janssen Robert (Senior Vice President) disposed off 15,000 shares at an average price of $6.33 for $94950.0. The insider now directly holds 177,266 shares of Dynavax Technologies Corporation (DVAX).
Dynavax Technologies Corporation (DVAX): Who are the competitors?
The company’s main competitors (and peers) include AstraZeneca PLC (AZN) that is trading 1.42% up over the past 12 months. Pfizer Inc. (PFE) is 0.92% up on the 1-year trading charts. Short interest in the company’s stock has fallen -12.9% from the last report on Nov 12, 2020 to stand at a total of 27.56 million short shares sold with a short interest ratio of 8.11.